Founded in 2005, Korea Institute for Pharmaceutical Policy Affairs, KIPPA, is a non-profit, public foundation, approved by the Korean Ministry of Health and Welfare. The institute is contributed by three relevant parties, the Korean Pharmaceutical Association (KPA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), and the Korea Pharmaceutical Distribution Association (KPDA).

KIPPA is a leading research center, which aims to promote public health through the development of policy regarding the rational use of medicines, pharmacy education, pharmacy practice, pharmaceutical industry, and pharmaceutical supply and distribution. In particular, we begin to develop ¡®a community pharmacy model as a health promotion center for community members¡¯. We are collecting and analysing big data accordingly to develop pharmacy-based policies, which pursue maximised pharmacy practice for all the Koreans.

In consequence, KIPPA will consistently implement research tailored to the promotion of health in the nation and worldwide. We kindly ask for supports from our fellow pharmacists, public and associations.

If you have any further enquiries about the institute or research in English, please contact us via e-mail (kippa.org@gmail.com).

Thank you.

Office Address
3FL, 194, Hyoryeong-ro, Seocho-gu, Seoul, Repbulic of Korea

ÇöÀçÀ§Ä¡ : Home : ¾Ë¸²¸¶´ç : ¿¬±¸¼Ò ´º½º
   
¾Ë¸²¸¶´ç
°øÁö»çÇ×
º¸µµÀÚ·á
ÀÎÀçä¿ë
 
 
Á¦   ¸ñ [´ëÇѾà»çÀú³Î]ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_°í·ÉÈ­¡¤¸¸¼ºÁúȯÀ¸·Î ÀÎÇÑ ÀǾàǰ ¼Òºñ º¯È­ 2
³»   ¿ë

°í·ÉÈ­¡¤¸¸¼ºÁúȯÀ¸·Î ÀÎÇÑ ÀǾàǰ ¼Òºñ º¯È­

2019³â OECDÀÇ ÇÑ´«¿¡ º¸´Â °Ç°­: ¾à»ç(å·ÞÀ) ºÎ¹®À» Áß½ÉÀ¸·Î 2

2020-05-25 06:00:53 ÁÖÇý¼º ±âÀÚ ÁÖÇý¼º ±âÀÚ hsjoo@kpanews.co.kr

<Áö³­È£¿¡  À̾>
¾à»ç¿Í ¾à±¹
¾à»ç´Â ¼ÒºñÀÚ ¹× È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÀǾàǰÀÇ °ø±ÞÀ» °ü¸®Çϰí ÀǾàǰÀÇ ¾ÈÀüÇϰí È¿°úÀûÀΠ»ç¿ëÀ» º¸ÀåÇÏ´Â ÈÆ·ÃµÈ º¸°ÇÀÇ·á Àü¹®°¡ÀÌ´Ù.
 
2000³âµµ¿Í 2017³â »çÀ̠Ȱµ¿ ¾à»çÀÇ ¼ö´Â OECD ±¹°¡µé¿¡¼­ Àα¸ 10¸¸ ¸í´ç 83¸íÀ¸·Î 33% Áõ°¡Çß´Ù<±×¸²4>. 


Àα¸ ´ç ¾à»çÀÇ ¼ö´Â ÀϺ»ÀÌ °¡Àå ³ô°í(Àα¸ 10¸¸ ¸í´ç 181¸í) ³×´ú¶õµå°¡ °¡Àå ³·´Ù(Àα¸ 10¸¸ ¸í´ç 21¸í). ÀϺ»ÀÇ µÎµå·¯Áø ¾à»ç ¼ö Áõ°¡´Â ÀǾàºÐ¾÷¿¡ ´ëÇÑ Á¤ºÎÀÇ ³ë·ÂÀ» ¹Ý¿µÇϰí ÀÖ´Ù.

OECD ±¹°¡¿¡¼­ ´ëºÎºÐÀÇ ¾à»ç´Â Áö¿ª ¼Ò¸Å¾à±¹¿¡¼­ ÀÏÇϰí ÀÖÀ¸³ª, ÀϺδ º´¿ø, Á¦¾à, ¿¬±¸, ¶Ç´Â Çмú ºÐ¾ß¿¡µµ Á¾»çÇϰí ÀÖ´Ù. Àα¸ 10¸¸ ¸í ´ç Áö¿ª¾à±¹ÀÇ ºÐÆ÷´Â 7°³(µ§¸¶Å©)ºÎÅÍ 88°³(±×¸®½º)±îÁö ÀÖÀ¸¸ç OECD Æò±Õ 29°³·Î ³ªÅ¸³­´Ù<±×¸²5>. 


¸î¸î ±¹°¡µéÀº º´¿ø¾à±¹ÀÇ ¿Ü·¡Åõ¾à ¼­ºñ½º¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô°í, ¾ÆÁ÷ ÀÇ»çµéÀ̠ȯÀڵ鿡°Ô Á÷Á¢ Åõ¾àÀ» Çϰí Àֱ⵵ ÇϹǷÎ(¿¹: ³×´ú¶õµå) ÀÌ·¯ÇÑ Â÷À̰¡ ³ªÅ¸³­´Ù.

Áö¿ª¾à±¹ ¾à»çµéÀÇ ¿ªÇÒÀº ±Ù·¡ ¸î ³â°£ º¯È­Çϰí ÀÖ´Ù. ÁֵȠ¿ªÇÒÀº ÀǾàǰÀÇ Åõ¾àÀÌÁö¸¸, ¾à»çµéÀº Áö¿ª¾à±¹°ú ÅëÇյȠº¸°ÇÀÇ·á ¼­ºñ½º Á¦°ø ÆÀ ³»¿¡¼­ È¯ÀÚµéÀ» ´ë»óÀ¸·Î Á¡Á¡ ´õ Á÷Á¢ÀûÀΠ¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù(¿¹: È£ÁÖ, ¾ÆÀÏ·£µå, ´ºÁú·£µåÀÇ µ¶°¨ ¿¹¹æÁ¢Á¾; È£ÁÖ, ÀϺ», ´ºÁú·£µå, ¿µ±¹ÀÇ º¹¾à¼øÀÀµµ Áö¿ø ¼­ºñ½º).

¿ì¸®³ª¶óÀÇ ¾à»ç ¼ö´Â OECD Æò±Õ°ú ºñ±³Çؼ­ ³·Àº ÆíÀ¸·Î ÁßÇÏÀ§±Ç¿¡ ¼ÓÇÏÁö¸¸, ¾à±¹ ¼ö´Â Àα¸ 10¸¸ ¸í´ç ¾à 41°³·Î(2015³â ±âÁØ) ÀÚ·á¿¡¼­ Á¦½ÃÇÑ OECD Æò±Õº¸´Ù ³ô´Ù. 

ÇØ¿ÜÀÇ °æ¿ì ´ëÇü ¾à±¹¿¡ ´Ù¼öÀÇ ¾à»ç°¡ °í¿ëµÅ ±Ù·ÎÀڷΠÀÏÇϴ °Í°ú ´Þ¸® 1ÀΠ°æ¿µ¹æ½ÄÀÇ ¼Ò±Ô¸ð ¾à±¹Ã¼°è°¡ ÁÖ¸¦ ÀÌ·ç°í Àִ Çѱ¹ÀÇ ÇöȲÀ» ¹Ý¿µÇϰí Àִ °ÍÀ¸·Î ÆÇ´ÜµÈ´Ù.

ÀǾàǰ ¼Òºñ(Pharmaceutical consupmtion)
°í·ÉÈ­¿Í ¸¸¼ºÁúȯÀ¸·Î ÀÎÇÑ ÀǾàǰ ¼ö¿ä Áõ°¡¿Í ÀÓ»óÀû »óȲÀÇ º¯È­·Î ÀǾàǰ ¼Òºñ´Â Áö³­ ¼ö½Ê ³â°£ Áõ°¡Ãß¼¼¸¦ º¸ÀδÙ. 

¿©±â¼­´Â ÀǾàǰÀÇ ³× °¡Áö Ä«Å×°í¸®; Ç×°íÇ÷¾ÐÁ¦, ÄÝ·¹½ºÅ×·Ñ ÀúÇÏÁ¦, ´ç´¢º´ Ä¡·áÁ¦, Ç׿ì¿ïÁ¦ÀÇ ¼Òºñ¿¡ ´ëÇØ ºÐ¼®Çß´Ù. ÀÌ Ä«Å×°í¸®´Â OECD ±¹°¡µé¿¡¼­ Áö³­ ¼ö½Ê ³â°£ À¯º´·üÀÌ °¡Àå Å©°Ô Áõ°¡ÇÑ ¾àÈ¿±ºµéÀÌ´Ù.

Ç×°íÇ÷¾ÐÁ¦ ¼Òºñ´Â 2000³âµµ¿Í 2017³âµµ »çÀÌ 70%°¡ Áõ°¡Çß´Ù. °¡Àå ³ôÀº ¼Òºñ¸¦ º¸À̴ µ¶Àϰú Çë°¡¸®´Â Çѱ¹°ú ÅÍŰÀÇ 5¹è¿¡ ÇØ´çÇÑ´Ù<±×¸²6>. ÀÌ·¯ÇÑ Â÷À̴ °íÇ÷¾Ð À¯º´·üÀÇ ¿µÇâµµ ¹Ý¿µÇÒ °ÍÀ¸·Î º¸ÀδÙ.


ÄÝ·¹½ºÅ×·Ñ ÀúÇÏÁ¦¿¡ ´ëÇÑ ¼Òºñ Áõ°¡´Â Ç×°íÇ÷¾ÐÁ¦º¸´Ùµµ Å©°Ô ³ªÅ¸³µÀ¸¸ç<±×¸²7> ´ç´¢º´ Ä¡·áÁ¦ÀÇ »ç¿ë ¶ÇÇÑ ±ÞÁõ, OECD ±¹°¡µé¿¡¼­ °ÅÀÇ µÎ ¹è°¡ Áõ°¡Çß´Ù<±×¸²8>. ´ç´¢º´ Ä¡·áÁ¦ ¼Òºñ Áõ°¡´Â À¯º´·ü Áõ°¡¿Í Á¦2Çü ´ç´¢¿Í ¹ÐÁ¢ÇÑ °ü·ÃÀÌ Àִ ºñ¸¸ÀÇ Áõ°¡·Î ¼³¸íÇÒ ¼ö ÀÖ´Ù.


Ç׿ì¿ïÁ¦ ¼Òºñ·® ¶ÇÇÑ OECD ±¹°¡µé¿¡¼­ µÎ ¹è°¡ Áõ°¡Çß´Ù<±×¸²9>. À̴ ¿ì¿ïÁõ¿¡ ´ëÇÑ ÀνĠº¯È­¿Í Ä¡·á °¡´É¼º, ÁøÈ­Çϴ ÀÓ»ó °¡À̵å¶óÀΠ±×¸®°í È¯ÀÚ ¹× ¼­ºñ½º Á¦°øÀڠŵµ º¯È­ÀÇ ¿µÇâÀ» ¹Þ¾Ò´Ù. ±×·¯³ª Ç׿ì¿ïÁ¦ ¼Òºñ·®Àº ±¹°¡º°·Î Å« Â÷À̸¦ º¸ÀδÙ. <´ÙÀ½È£¿¡ °è¼Ó>



 

¹øÈ£ ÷ºÎ Á¦¸ñ ÀÛ¼ºÀÚ ÀÛ¼ºÀÏ Á¶È¸
39 [¸Þµð°ÔÀÌÆ®] "Äڷγª19 À¯Çà ³¡³ªµµ ¹é½Å ¿¬±¸°³¹ß °è¼Ó..3000¸¸¸íºÐ ±¹°¡ ºñÃà" ±è¼±Èñ 2020-05-29 1103
38 [¾à¾÷½Å¹®] ¡°Äڷγª19 Ä¡·áÁ¦¡¤¹é½Å, °æÀïÁ¦Ç° ºñ±³¿ìÀ§ È®º¸ Çʼö¡± ±è¼±Èñ 2020-05-29 1141
37 [¾à¾÷½Å¹®] Äڷγª19 ¹é½Å º¸À¯·® Àü ±¹¹Î 52~62% ¼öÁØ µÅ¾ß ±è¼±Èñ 2020-05-29 931
36 [ÄíŰ´º½º] ¡°Äڷγª19 ¹é½Å °³¹ß¡¤ºñÃà, Á¤ºÎ °³ÀÔ ÇʼöÀû¡± ±è¼±Èñ 2020-05-29 801
35 [Àϰ£º¸»ç] ¡®Äڷγª19, Àü ±¹¹Î 60% Á¢Á¾ÇÒ ¹é½Åȯ°æ ±¸ÃàµÅ¾ß¡¯ ±è¼±Èñ 2020-05-29 676
34 [µ¥Àϸ®ÆÊ]"±¹¹Î 60%°¡ ¹é½Å ¸Â¾Æ¾ß Äڷγª19 À¯Çà ¸·´Â´Ù" ±è¼±Èñ 2020-05-29 715
33 [¾à»ç°ø·Ð] ÀǾàǰÁ¤Ã¥¿¬, ¡®Äڷγª19 Ä¡·áÁ¦ ¹× ¹é½Å°³¹ß¡¯ ÁÖÁ¦ Æ÷·³ °³ÃÖ ±è¼±Èñ 2020-05-29 693
32 [´ëÇѾà»çÀú³Î]ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_°í·ÉÈ­¡¤¸¸¼ºÁúȯÀ¸·Î ÀÎÇÑ ÀǾàǰ ¼Òºñ º¯È­ 2 ±è¼±Èñ 2020-05-25 783
31 [´ëÇѾà»çÀú³Î] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®_2019³â OECD ÇÑ´«¿¡ º¸´Â °Ç°­(Health at a Glance) 1 ±è¼±Èñ 2020-05-25 881
30 [µ¥Àϸ®ÆÊ] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò, Áúº» ¹ßÁÖ ±¹°¡¹é½Å ¿¬±¸ Âü¿© ±è¼±Èñ 2020-05-21 996
29 [º¸°Ç´º½º] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¡®±¹°¡¹é½Å ¼ö±Þ ¸ð´ÏÅ͸µ ¹× ¼ö¿ä ¿¹Ãø ¸ðµ¨¸µ¡¯ »ç¾÷ Âü¿© ±è¼±Èñ 2020-05-21 844
28 [¸ÞµðÆÄ³ª´º½º] ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò, ±¹°¡¹é½Å ¼ö±Þ ¸ð´ÏÅ͸µ »ç¾÷ Âü¿© ±è¼±Èñ 2020-05-21 703
27 [Àϰ£º¸»ç] ¿ì¸®³ª¶ó ÀǾàǰ ¼Òºñ Áõ°¡À² ¡®ÃÖ»óÀ§¡¯ ±è¼±Èñ 2020-05-15 971
26 [µ¥Àϸ®ÆÊ] Àα¸ 10¸¸¸í´ç ¾à±¹¼ö, OECD Æò±Õº¸´Ù 1.4¹è ³ô¾Æ ±è¼±Èñ 2020-05-15 1199
25 [¸Þµð°ÔÀÌÆ®]¾à±¹ 1ÀÎ °æ¿µ ¹æ½Ä À§ÁÖ.."OECD ´ëºñ ¾à±¹ ¼ö´Â ¸¹Áö¸¸ ¾à»ç´Â Æò±Õ ÀÌÇÏ" ±è¼±Èñ 2020-05-15 791

ÀÌÀü 10ÆäÀÌÁö [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  ´ÙÀ½ 10ÆäÀÌÁö

 
 

¼­¿ï ¼­Ãʱ¸ È¿·É·Î194, 3Ãþ (Àç)ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò TEL : 02) 3474-5301 / FAX : 02)3474-5306

COPYRIGHT (C) 2006 KOREA INSTITUTE FOR PHARMACEUTICAL POLICY AFFAIRS ALL RIGHTS RESERVED. FOR MORE INFORMATION MAL kippa.org@gmail.com

±âºÎ±Ý ¾È³»